MedPath

Assessing the impact of personalised risk estimates on the uptake and timing of risk management options in women who have inherited a change in genes associated with an increased risk of breast and ovarian cancer

Not Applicable
Conditions
Hereditary breast and ovarian cancer
Cancer
Registration Number
ISRCTN15331714
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Brief Summary

2022 Protocol article in https://doi.org/10.3390/cancers14112716 (added 21/06/2022)

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
Female
Target Recruitment
600
Inclusion Criteria

1. Female
2. Age >18 years
3. Undergoing predictive testing for a PV in BRCA1, BRCA2, PALB2, ATM or CHEK2
4. Able to give informed consent

Exclusion Criteria

Previous history of breast cancer or ovarian cancer

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath